This report describes an asymptomatic perforation with the GyneFix ® intrauterine contraceptive implant. A review of all other reports of this complication has been performed. Analysis of these reports suggests prolonged amenorrhoea secondary to continuous progestogen use as a possible common predisposing factor.
Discussion
The GyneFix is a flexible, frameless, intrauterine contraceptive implant that is anchored to the fundal myometrium by a polypropylene knot and has been used in the UK since 1997. It was designed to reduce the incidence of common problems associated with IUDs, namely expulsion, bleeding and pain. This is the sixth case report of a perforation with this device (Table 1) . Overall, five of the devices were removed either laparoscopically or by laparotomy. The remaining device was thought to have been passed out of the abdomen via the intestines. 1 Copper IUDs such as the GyneFix are thought to predispose the patient to adhesions once inside the peritoneal cavity. It is this adhesion risk, coupled with the patients' concern about the presence of a foreign object free in their abdomen, which leads to the devices being retrieved in theatre. The manufacturers of GyneFix recommend that perforated devices should be removed.
Notably four of the six reports mention previous use of long-term progestogen contraception; two with DepoProvera, 1 one with Norplant ®2 and one with the progestogen-only pill. 3 The other two cases do not state the type of contraception used. 3, 4 One of the previous cases speculates as to whether prolonged amenorrhoea may cause myometrial hypoplasia and thus make perforation more likely. 3 The manufacturers of the device list hypoplastic uterus as a contraindication to insertion but do not recommend routine scanning to determine fundal myometrial thickness. Their advice is to scan any patient in whom there is any Perforation with the GyneFix ® intrauterine implant: is there a common factor? Thomas R Aust, MB ChB, Research Fellow suspicion of perforation but in our case the perforation was asymptomatic and only the request to have the GyneFix removed allowed the diagnosis to be made.
Unlike most IUDs the GyneFix has to be anchored by penetrating a knot into the uterine muscle. It is possible that uterine hypoplasia after long-term progestogens could make these patients more prone to perforation with this particular device. A representative of the company that developed the GyneFix has suggested that the likely mechanism of perforation is that the anchoring knot is placed on the serosal surface of the uterus at the time of insertion and the device is pulled into the abdominal cavity by bowel action.
5 However, any theory on the mechanism of perforation can only be conjecture.
The design of the introducer was altered in 2001 to make GyneFix insertion a one-handed procedure, thereby freeing the other hand to provide traction on the tenaculum. This alteration was to make insertion easier and, it could be argued, to make perforation less likely. It is impossible to say which version of introducer was used in the previous cases (although they are likely to have been the older model) but one of the new introducers was used in the present case.
The GyneFix has been found to be a well-accepted form of non-hormonal contraception. 6 Routine ultrasound scanning of all patients undergoing GyneFix insertion would be impractical and would impede the convenience and acceptability of this device. However, one has to question whether a history of prolonged amenorrhoea should prompt caution or the assessmen t of fundal myometrial thickness before insertion. This is especially important as perforation may be difficult to diagnose and may only present when the patient becomes pregnant. 
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Case Report
Case report
A 16-year-old girl currently using Depo-Provera ® for contraception attended the family planning clinic with a view to a change of contraceptive method because of weight gain on Depo-Provera. She was informed of her contraceptive options and in particular the contraceptive implant, Implanon. Implanon is a single-rod, nonbiodegradable, contraceptive implant containing 68 mg etonogestrel. The mode of action, insertion and removal method and side effects including menstrual disturbance were fully explained to her. She consented to insertion. Implanon was inserted using the standard method into the medial side of her right arm, 8 cm above the elbow in the biceps/triceps groove. 1 After insertion the implant was impalpable. The patient was informed that it was possible that the implant was too deep to palpate or perhaps had not left the loading system. She was protected from pregnancy by her still active DepoProvera.
An ultrasound of the patient's upper arm failed to detect the implant. X-ray was not utilised as Implanon is not radioopaque. As the ultrasound department was not familiar with ultrasound use in the location of Implanon and deep insertion could not be confidently excluded, a magnetic resonance imaging (MRI) scan was recommended.
In the meantime a further Implanon was inserted, with the patient still under contraceptive cover from the DepoProvera.
The MRI scan revealed a single device in the subcutaneous fat. Localisation was aided by placing an oil capsule on the skin, at the site of insertion. A surface coil is necessary for the best image quality. Figure 1 shows the Implanon in axial section, as a low signal (black) structure, or signal void, just beneath the skin, with surrounding high signal (white) rim. Higher signal from the adjacent subcutaneous fat acts as contrast. Figure 2 is a coronal section using a fat suppression sequence (STIR). The Implanon has a low signal, and would be lost against the background low signal of subcutaneous fat, but is highlighted by a ragged high signal rim. This high signal represents the oedema following insertion, which persists for several days.
The patient was informed that she did only have one
